Prediction of metabolic syndrome by visceral adiposity index, lipid accumulation product and model of adiposity index amongst infertile women with and without polycystic ovary syndrome

Pikee Saxena; Jyoti Gaur; Archana Mishra; Anju Jain

doi:10.18203/2320-1770.ijrcog20230540

Authors

Pikee Saxena Department of Obstetrics and Gynecology, Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital, New Delhi, India
Jyoti Gaur Departemnt of Clinical Research, Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital, New Delhi, India
Archana Mishra Department of Obstetrics and Gynecology, Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital, New Delhi, India
Anju Jain Departement of Biochemistry, Lady Hardinge Medical College and Smt. Sucheta Kriplani Hospital, New Delhi, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20230540

Keywords:

LAP, Metabolic syndrome, MOAD, PCOS, VAI

Abstract

Background: This study was conducted to compare visceral adiposity index (VAI), lipid accumulation product (LAP) and model of adiposity index (MAOD) for prediction of metabolic syndrome (MS) amongst infertile women with and without PCOS.

Methods: It was a case control, retrospective study performed in gynecology outpatient department of a tertiary care center. Total 143 infertile women with PCOS and 367 infertile women without PCOS were recruited in the study. Waist circumference (WC), BMI, waist hip ratio (WHR), insulin resistance, VAI, LAP, MOAD were assessed in both groups.

Results: Significantly higher values of WC, WHR, systolic BP, insulin postprandial and all 3 adiposity indices were found among infertile women with PCOS as compared to women without PCOS. In hormonal profile, testosterone, AMH, FSH, prolactin, estradiol was found to be significantly higher in PCOS group. For predicting MS in PCOS women, VAI had the highest AUC 0.878 with a cut off value of 3.1, highest sensitivity of 88.9%, specificity of 90.7%, positive and negative predictive value of 76.2% and 96% respectively followed by LAP and MOAD.

Conclusions: To conclude, all three adiposity indexes VAI, LAP and MOAD were significantly raised in PCOS women. VAI followed by LAP were the best indicators to predict metabolic syndrome in women with PCOS.

Metrics

Metrics Loading ...

References

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237-45.

Asuncion M, Calvo RM, San Millan JL. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434-8.

Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:266-272.

Ormazabal V, Nair S., Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17:122.

Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb. 2005;12:295-300.

Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol. 2000;52:595-600.

Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Withdrawn: postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health- National heart, lung, and blood institute sponsored women’s ischemia syndrome evaluation. J Clin Endocrinol Metab. 2008;93(4):1276-84.

Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95(5):2038-49.

Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440-7.

The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.

Strauss JF. Some new thoughts on the pathophysiology and genetics of polycystic ovarian syndrome. Ann New York Acad Sci. 2003;997(1):42-8.

De Leo V, Musacchio MC, Palermo V, Di Sabatino A, Morgante G, Petraglia F. Polycystic ovary syndrome and metabolic co-morbidities: therapeutic options. Drugs Today. 2009;45:763-75.

Redmond GP, Bergfeld WF. Diagnostic approach to androgen disorders in women: acne, hirsutism and alopecia. Cleve Clin J Med. 1990;57(5):423-7.

Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol. 2005;106:1317.

Saxena P, Prakash A, Nigam A, Mishra A. Polycystic ovary syndrome: a clinical, hormonal, and metabolic assessment in relation to body mass index. Indian J Endocrinol Metab. 2012;16(6).

Mandrelle K, Kamath MS, Bondu DJ, Chandy A. Prevalence of metabolic syndrome in women with polycystic ovary syndrome attending an infertility clinic in a tertiary care hospital in south India. J Hum Reprod Sci. 2012;5(1):26-31.

Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol. 2006;65:137-45.

Hirschberg AL. Polycystic ovary syndrome, obesity and reproductive implications. Women Health. 2009;5(5):529-40.

Androulakis I, Kandaraki E, Christakou C, Karachalios A, Marinakis E, Paterakis T, et al. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. Clin Endocrinol. 2014;81(3):426-31.

Tehrani FR, Minooee S, Azizi F. Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: a population-based study. Eur J Endocrinol. 2014;171(2):199-207.

Zheng SH, Li XL. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS. Gynecol Endocrinol. 2016;32(3):177-83.

Adanas G, Özgen G. The relation of visceral adiposity index and lipid accumulation product with metabolic, anthropometric, and hormonal parameters in patients with polycystic ovary syndrome. J Surg Med. 2020;4(8):664-8.

Abruzzese GA, Cerrrone GE, Gamez JM, Graffigna MN, Belli S, Lioy G, et al. Lipid accumulation product (LAP) and visceral adiposity index (VAI) as markers of insulin resistance and metabolic associated disturbances in young Argentine women with polycystic ovary syndrome. Metab Res. 2017;49(1):23-9.

Borruel S, Molto JF, Alpanes M, Fernandez-Duran E, Alvarez-Blasco F, Luque-Ramirez M, et al. Surrogate markers of visceral adiposity in young adults: waist circumference and body mass index are more accurate than waist hip ratio, model of adipose distribution and visceral adiposity index. PloS One. 2014;9(12):e114112.